Try a new search

Format these results:

Searched for:

in-biosketch:true

person:adamss04

Total Results:

125


Recent advances in dendritic cell biology

Adams, Sylvia; O'Neill, David W; Bhardwaj, Nina
Dendritic cells are professional antigen presenting cells that are central to the induction and regulation of immunity. This review discusses recent advances in the understanding of dendritic cell biology.
PMID: 16118915
ISSN: 0271-9142
CID: 58180

Recent advances in dendritic cell biology

Adams, Sylvia; O'Neill, David W; Bhardwaj, Nina
Dendritic cells are professional antigen presenting cells that are central to the induction and regulation of immunity. This review discusses recent advances in the understanding of dendritic cell biology
PMID: 15821885
ISSN: 0271-9142
CID: 55977

Manipulating dendritic cell biology for the active immunotherapy of cancer

O'Neill, David W; Adams, Sylvia; Bhardwaj, Nina
Dendritic cells (DCs) are specialized antigen-presenting cells (APCs) that have an unequaled capacity to initiate primary immune responses, including tolerogenic responses. Because of the importance of DCs in the induction and control of immunity, an understanding of their biology is central to the development of potent immunotherapies for cancer, chronic infections, autoimmune disease, and induction of transplantation tolerance. This review discusses recent advances in DC research and the application of this knowledge toward new strategies for the clinical manipulation of DCs for cancer immunotherapy
PMID: 15231572
ISSN: 0006-4971
CID: 47843

Maturation matters: importance of maturation for antitumor immunity of dendritic cell vaccines [Letter]

Adams, Sylvia; O'Neill, David; Bhardwaj, Nina
PMID: 15365084
ISSN: 0732-183x
CID: 63123

Novel therapeutic agents under investigation for malignant melanoma

Pavlick, Anna C; Adams, Sylvia; Fink, Matthew A; Bailes, Amanda
Malignant melanoma presents a therapeutic challenge. Patients at high risk for recurrence (stage III) are eligible for adjuvant treatment with IFN-alpha or may enrol in a clinical trial. Both options offer no meaningful survival advantage. Patients with metastatic disease (stage IV) have a 5-year survival of < 10% and have no effective treatment options. Despite aggressive investigations into vaccine therapy, no vaccine has yet received FDA approval. Biological therapies with IFN-alpha and IL-2 have demonstrated a real but minimal effect. Chemotherapeutic options are even more dismal. Single-agent chemotherapy yields a 15-20% response rate of short lived duration. Combination chemotherapy alone or with immunological adjuvants yields response rates of 35-45% but with significant toxicity and no significant improvement in survival. Novel treatment agents that target metabolic pathways, angiogenesis inhibitors, antisense therapies, gene therapies and innovative vaccines may offer hope for an otherwise grave disease
PMID: 12943498
ISSN: 1354-3784
CID: 44834